ストックスクリーナーアプリを入手
68.29
1.04%
0.70
プレマーケット:
68.91
0.62
+0.91%
前日終値:
$67.59
開ける：
$67.72
24時間の取引高:
395.58K
Relative Volume:
0.30
時価総額：
$7.24B
収益：
$628.56M
当期純損益:
$141.82M
株価収益率:
54.20
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
-3.63%
1か月 パフォーマンス:
-7.70%
6か月 パフォーマンス:
+13.84%
1年 パフォーマンス:
+95.84%
1日の値動き範囲:
$67.53
$68.67
1週間の範囲:
$67.44
$71.57
52週間の値動き範囲:
$32.33
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
68.29 | 7.17B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) - Yahoo Finance
When is Corcept Therapeutics Incorporated stock expected to show significant growthCapitalize on momentum-driven investment opportunities - jammulinksnews.com
What are the technical indicators suggesting about Corcept Therapeutics IncorporatedInvest confidently with professional market insights - jammulinksnews.com
Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFree Investment Community - jammulinksnews.com
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk - Yahoo Finance
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Corcept Therapeutics’ ALS Study: A Potential Game-Changer? - TipRanks
Should I buy Corcept Therapeutics Incorporated stock before earningsHigh-octane financial growth - jammulinksnews.com
Is Corcept Therapeutics Incorporated a good long term investmentConsistent high-performance stocks - PrintWeekIndia
What drives Corcept Therapeutics Incorporated stock priceUnbelievable profit margins - PrintWeekIndia
What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional
Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo.co
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance
Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - Yahoo Finance
FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News
M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser
How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals
Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha
Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest
Corcept Therapeutics Submits New Drug Application to FDA - TipRanks
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN
Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada
Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN
13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey
A New Dawn in Diabetes Treatment: Corcept Therapeutics' Korlym and the Untapped $2.8 Billion Opportunity - AInvest
Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada
Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):